| (AbbVie) M24-108 | A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT05650632 |
| (AstraZeneca) D7230C00001 | A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma | Dr Hira Mian | Open to recruitment | NCT06106945 |
| (BeiGene) BGB-11417-301 / CELESTIAL TN-CLL | A Phase 3, Open-label, Randomized Study of BGB-11417 plus Zanubrutinib Compared with Venetoclax plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Dr Christopher Hillis | Suspended/On hold | NCT06073821 |
| (BMS) CA089-1043 / KarMMa-9 | A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | Dr Amaris Balitsky | Open to recruitment | NCT06045806 |
| (CCTG) HD.11 | A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma | Dr Amaris Balitsky | Open to recruitment | NCT05180097 |
| (CCTG) LY.17 | A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Dr Graeme Fraser | Open to recruitment | NCT02436707 |
| (CCTG) MY.13 | A PHASE III NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL OF FIXED DURATION VERSUS CONTINUOUS DARATUMUMAB AMONG TRANSPLANT INELIGIBLE OLDER ADULTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA | Dr Hira Mian | Open to recruitment | NCT06182774 |
| (CCTG) SC.26 / EASE | Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia | Dr Alejandro Garcia-Horton | Open to recruitment | NCT04224974 |
| (EMN) EMN28 / 68284528MMY3005 / CARTITUDE-6 | A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible | Dr Mohammed Aljama | Open to recruitment | NCT05257083 |
| (Genentech) GO42552 / CAMMA 1 | AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLUS DARATUMUMAB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (CAMMA 1) | Dr Hira Mian | Open to recruitment | NCT04910568 |
| (Janssen) 64407564MMY3009 / MonumenTAL-6 | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P),Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator’s Choice of EitherElotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, andDexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | Dr Hira Mian | Open to recruitment | NCT06208150 |
| (Pfizer) C1071007 / MAGNETISMM-7 | A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION | Dr Mohammed Aljama | Open to recruitment | NCT05317416 |
| (SHSC) 3242 / BRAWM | A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom’s Macroglobulinemia | Dr Mohammed Aljama | Open to recruitment | NCT04624906 |
| (Syros) SY-1425-301 / SELECT-MDS-1 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome | Dr Brian Leber | Open to recruitment | NCT04797780 |
Find a Trial
Contact Us